Company news

Defence Therapeutics Inc Class A (CSE:DTC) news

Defence Therapeutics Inc Class A news releases on 6ix. Latest, Oct 1, 2026: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next…

Defence Therapeutics Inc Class A (CSE:DTC) news

Press releases & updates

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Defence Therapeutics Provides Updates on Sharing Agreement

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

Defence Therapeutics : Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Defence Therapeutics Announces Grant of Restricted Stock Units

EARLY WARNING REPORT FILED PURSUANT TO NATIONAL INSTRUMENT 62-103

Defence Therapeutics Announces Warrant Terms Amendment

Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform

Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline

Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics

Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th

Defence Therapeutics Announces AGM Results and Provides Corporate Updates

Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs

Defence Therapeutics Announces Convertible Debenture Conversion

Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology

Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025

Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin

Defence Therapeutics Appoints Dr. Amie Phinney as Director

Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000

Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth

Defence Therapeutics Announces Debenture Units Financing

Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

Defence Therapeutics to Attend Bio International Convention in Boston, June 2025

Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies

Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer

DATEX TECHNOLOGIES CORPORATION ANNOUNCES THE COMPLETION OF ITS GOING PRIVATE TRANSACTION

DATEX TECHNOLOGIES CORPORATION ANNOUNCES THE APPROVAL BY SHAREHOLDERS OF ITS GOING PRIVATE TRANSACTION

DATEX TECHNOLOGIES CORPORATION ANNOUNCES ITS INTENTION TO COMPLETE A GOING PRIVATE TRANSACTION

Datex Technologies Corporation announces appointment of David Parkes to board of directors

Mr. Oren Vered resigns as Director of Montec Holdings Inc.